Insulin therapy in T1DM can reduce TG and TRL, especially in patients with poor glycaemic control [89], whereas sulfonylureas, peroxisome proliferator-activated receptor gamma (PPAR) agonist (thiazolidinediones), SGLT2 inhibitors, dipeptidyl-peptidase 4 (DPP4) inhibitors, GLP-1 receptor agonists and metformin can significantly reduce TG [4]. The gene discussed is DPP4; the disease is type 1 diabetes mellitus.